How Does Mazdutide Work? Mechanism of Action, Per the Research

What mazdutide is, in regulatory terms

Mazdutide is a prescription medicine. A 2025 drug profile reported that mazdutide received its first regulatory approval in China in 2025, with ongoing clinical development programmes in additional indications and settings (PMID 41028652). Outside the markets where it has been authorised, it remains an investigational medicine evaluated in clinical trials. Reviews of the obesity pharmacotherapy landscape list it alongside other peptide agonists and polyagonists that reached late-stage testing (PMID 39952695, PMID 39305981). Whether any individual is a candidate for a prescription medicine of this class is a question for a licensed prescribing clinician, not for an educational summary.

Background on the molecule, its trial programme and its reported findings sits on the companion overview page: mazdutide research overview.

The short answer: a dual receptor agonist modelled on oxyntomodulin

Mazdutide is described in the published literature as a synthetic peptide analogue of oxyntomodulin, a naturally occurring gut hormone that binds both the GLP-1 receptor and the glucagon receptor, engineered with a fatty acid side chain that supports once-weekly subcutaneous administration (PMID 41028652). Reviews of novel GLP-1-based medicines group it with dual and triple agonists whose defining feature is simultaneous engagement of more than one metabolic hormone receptor rather than a single target (PMID 41054801).

In other words, the mechanistic question "how does mazdutide work" has two halves that the literature treats separately: what GLP-1 receptor agonism does, and what adding glucagon receptor agonism is proposed to add on top of it.

Receptor targets at a glance

Established mechanism: GLP-1 receptor agonism

The GLP-1 arm of mazdutide's pharmacology is the better characterised of the two, because it is shared with an entire approved drug class. Reviews of GLP-1-based medicines describe the receptor as a class B G protein-coupled receptor that signals mainly through Gs and cyclic AMP, with downstream protein kinase A and Epac2 activity in pancreatic beta cells, producing insulin secretion that scales with ambient glucose rather than occurring unconditionally (PMID 41054801). That glucose dependence is the standard pharmacological explanation given in reviews for why agents in this class carry a low intrinsic hypoglycaemia signal when used without insulin or sulfonylureas (PMID 41054801).

Beyond the islet, reviews of hormone-based anti-obesity medicines describe GLP-1 receptor expression in the gastrointestinal tract and in central nervous system regions involved in energy balance, with slowed gastric emptying and reduced food intake reported as the principal routes by which this class influences body weight (PMID 39676791). Reviews of emerging obesity pharmacotherapy summarise the same appetite-centred account across the agents they assessed (PMID 39952695).

The second arm: glucagon receptor agonism

Glucagon on its own is a counter-regulatory hormone associated with hepatic glucose output, which makes dual agonism counterintuitive at first reading. The explanation offered in reviews of polyagonist design is one of balance: the GLP-1 component is intended to offset the glycaemic consequence of glucagon receptor activation, while the glucagon component contributes to energy expenditure and hepatic substrate handling (PMID 39952695, PMID 41054801). The drug profile for mazdutide described the molecule explicitly as a GLP-1 and glucagon receptor dual agonist developed for weight management and glycaemic indications (PMID 41028652).

Whether the balance holds in people is an empirical question, and the trial programme is where it was tested. In a phase 2 randomised, double-blind, placebo-controlled trial in Chinese patients with type 2 diabetes, researchers reported greater reductions in glycated haemoglobin with mazdutide than with placebo across the dose levels studied (PMID 37943529). Later randomised trials in Chinese adults with type 2 diabetes compared mazdutide with placebo and with the GLP-1 receptor agonist dulaglutide, and reported improvements in glycaemic measures with mazdutide in those comparisons (PMID 41407859, PMID 41407860). Those results are the practical evidence that glucagon receptor engagement at the doses tested did not override the glucose-lowering effect of the GLP-1 component.

Established mechanism versus proposed mechanism

• Established in the pharmacology literature: mazdutide binds and activates both the GLP-1 receptor and the glucagon receptor, and its long-acting structure supports weekly subcutaneous administration (PMID 41028652).
• Established for the class: GLP-1 receptor agonism acts through cyclic AMP signalling to influence glucose-dependent insulin secretion, gastric emptying and central appetite circuits (PMID 41054801, PMID 39676791).
• Proposed, and framed as such in reviews: the idea that the glucagon arm adds meaningful human energy expenditure and hepatic fat mobilisation on top of appetite suppression is presented in reviews of emerging obesity pharmacotherapy as a rationale for dual agonist design rather than as a settled quantitative account (PMID 39952695).
• Still being mapped: reviews of the broader effects of obesity medications discuss organ-level consequences beyond weight itself, and describe this as an area of active investigation (PMID 42208956).

What the clinical trials add to the mechanistic picture

Mechanism is inferred from pharmacology, but it is constrained by what randomised trials report. In a once-weekly trial in Chinese adults with obesity or overweight, researchers evaluated mazdutide at 4 mg and 6 mg against placebo over 48 weeks and reported significantly greater reductions in body weight in the mazdutide groups than in the placebo group (PMID 40421736). A systematic review and meta-analysis of randomised controlled trials covering diabetic and non-diabetic participants reported weight reduction with mazdutide relative to comparators across the pooled studies (PMID 38440786). An updated network meta-analysis of seven GLP-1 receptor agonists and polyagonists placed the various agents, including dual agonists, on a common comparative footing for weight outcomes in obesity or overweight (PMID 39305981).

Two caveats matter for mechanistic reading. First, the pivotal trials summarised above were conducted in Chinese adult populations, and a review of obesity in China discussed how population characteristics shape the interpretation and generalisability of such programmes (PMID 41389801). Second, a trial that reports a change in body weight or glycated haemoglobin does not isolate which receptor arm produced it. Attributing a given percentage of effect to glucagon receptor agonism specifically requires dedicated mechanistic work, and the reviews that describe the dual agonist rationale present it in those terms (PMID 39952695, PMID 41054801).

Adverse Events: What Studies Report

Mechanism and tolerability are linked, because slowed gastric emptying and central appetite signalling are also the most common route to unwanted effects in this class. In the once-weekly trial in Chinese adults with obesity or overweight, the study reported that gastrointestinal adverse events, including nausea, diarrhoea and vomiting, were the most frequently observed events and were mostly mild to moderate in severity (PMID 40421736). A systematic review and meta-analysis of randomised controlled trials of mazdutide similarly reported a higher frequency of gastrointestinal adverse events with mazdutide than with comparators (PMID 38440786). The phase 2 trial in Chinese patients with type 2 diabetes also reported safety and tolerability findings alongside its glycaemic results (PMID 37943529). Reviews of the drug class discuss gastrointestinal effects as the characteristic tolerability signal for GLP-1-based medicines generally (PMID 41054801). Individual risk assessment, contraindications and monitoring are matters for a prescribing clinician who can review a full medical history.

Open questions in the mechanism literature

1. How much of the effect is glucagon-driven? Reviews describe increased energy expenditure as the theoretical contribution of the glucagon arm, while noting that dual agonists are compared in trials against placebo or other agents rather than against their own single-receptor equivalents in most settings (PMID 39952695).
2. How do effects extend beyond adipose tissue? A review of obesity medications examined multisystem consequences beyond weight reduction and framed several organ-level questions as areas still under study (PMID 42208956).
3. How does mazdutide rank against other agents? A network meta-analysis compared multiple GLP-1 receptor agonists and polyagonists for weight outcomes, and indirect comparisons of this kind carry the usual limitations of differing trial populations and designs (PMID 39305981).
4. How will the evidence base broaden? The drug profile recorded ongoing clinical development beyond the first approved indication (PMID 41028652).

Summary of the mechanism as published

Across the sources above, the consistent description is this: mazdutide is a long-acting oxyntomodulin-based peptide that activates the GLP-1 receptor and the glucagon receptor, both Gs-coupled class B receptors signalling through cyclic AMP (PMID 41028652, PMID 41054801). GLP-1 receptor activity is the established contributor to glucose-dependent insulin secretion, delayed gastric emptying and reduced food intake (PMID 39676791). Glucagon receptor activity is the proposed contributor to hepatic lipid handling and energy expenditure, and randomised trials reported that glycaemic measures improved rather than worsened with the combination (PMID 37943529, PMID 41407859).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, including whether a prescription treatment is appropriate, what it involves and how it should be monitored.

References

• Mazdutide: First Approval (Drugs, 2025)
• Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (The New England Journal of Medicine, 2025)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article (Indian Journal of Endocrinology and Metabolism, 2024)
• Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial (Diabetes Care, 2024)
• Mazdutide versus placebo in Chinese adults with type 2 diabetes (Nature, 2026)
• Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes (Nature, 2026)
• Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials (Frontiers in Endocrinology, 2024)
• Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials (Metabolism, 2024)
• Beyond weight loss: multisystem benefits of obesity medications (The Lancet Diabetes & Endocrinology, 2026)
• Obesity in China: current progress and future prospects (The Lancet Diabetes & Endocrinology, 2026)